Compare SLDB & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLDB | ATEC |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2017 | 2006 |
| Metric | SLDB | ATEC |
|---|---|---|
| Price | $9.29 | $9.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $16.36 | ★ $22.00 |
| AVG Volume (30 Days) | 893.5K | ★ 2.2M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.97 | 15.04 |
| EPS | N/A | ★ N/A |
| Revenue | $8,094,000.00 | ★ $101,739,000.00 |
| Revenue This Year | N/A | $18.97 |
| Revenue Next Year | N/A | $16.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $6.82 |
| 52 Week High | $11.45 | $23.29 |
| Indicator | SLDB | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 49.52 |
| Support Level | $6.25 | $8.90 |
| Resistance Level | $11.45 | $9.75 |
| Average True Range (ATR) | 0.45 | 0.44 |
| MACD | 0.09 | -0.05 |
| Stochastic Oscillator | 66.77 | 28.19 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.